Vall d'Hebron Institute of Oncology (VHIO) is a center of biomedical research with scientists and physicians working together at the nexus of basic science and clinical research. Its main purpose is to promote and develop research excellence relating to oncological diseases. VHIO also pursues to make contributions to the development of new and better therapies for the treatment of cancer.
Subscribe to rss feed
In today's current era of precision medicine against cancer, research is successfully potentiating and personalizing immunotherapy to unleash the power of the immune system in a greater number of patients to attack disease. ...
Oct 17, 2019
0
4
With an estimated 570,000 cases and 311,000 deaths in 2018 worldwide, cervical cancer currently ranks as the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women. Furthermore, patients ...
Sep 30, 2019
0
2
Results from a study spearhead by researchers at the Vall d´Hebron Institute of Oncology (VHIO), show that the blockade of the multi-functional cytokine LIF induces tumor-infiltrating T cells to target and eliminate cancer. ...
Jun 11, 2019
0
54
Cutting-edge sequencing technology has revolutionized cancer diagnosis and since identified several so-called cancer driver genomic aberrations. This has led to the development of an extensive and powerful arsenal of anti-cancer ...
Mar 20, 2019
0
27
Not so long ago, immunotherapy against cancer was positioned as an emerging or even promising treatment, but not one with a proven track record. Today however, novel immunotherapeutics across different tumor types, either ...
Oct 03, 2018
0
128
Research spearhead by first author Isabel Puig, Post-Doctoral Fellow of the Vall d´Hebron Institute of Oncology's (VHIO) Stem Cells & Cancer Group, directed by Principal Investigator Héctor G. Palmer, has culminated in ...
Jun 26, 2018
0
4
Mosaic Biomedicals SL today announced a merger with Northern Biologics Inc. that will enable the accelerated development of MSC-1, a humanized antibody expected to begin clinical trials across several tumor types in 2017, ...
Dec 19, 2016
0
0
Published in JAMA Oncology, Principal Investigator of Vall d´Hebron Institute of Oncology´s (VHIO) Translational Genomics Group, Team Leader of translational genomics and targeted therapeutics in solid tumors at the August ...
Jun 09, 2016
0
4
